I’ve talked a lot on this blog about how important stem cell therapy will become in the future, and their enormous potential in treating previously untreatable diseases. Truly, I believe that stem-cell breakthroughs (as well as CRISPR gene editing technology!) will define the scientific accomplishments of our time.
According to the Wall Street Journal, Bayer AG (a pharmaceutical giant based in Germany) and Versant Ventures (a US health care investor) are planning on establishing a joint stem-cell research company. This is significant for two reasons; first, because it is just another testament to the potential of stem cell technology, and second, because it marks the latest effort by a big pharmaceutical company to develop novel drugs by pairing up with smaller biotechnology companies.